Dysentery, Bacillary clinical trials
The registry lists 61 studies for Dysentery, Bacillary across more than 10 countries. 6 are recruiting or about to start. 46 of them are mainly about Dysentery, Bacillary (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-26.
Get an email when these change. Save the Dysentery, Bacillary studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
PATH (7) · LimmaTech Biologics AG (5) · University of Maryland, Baltimore (5) · U.S. Army Medical Research and Development Command (4) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (4) · GlaxoSmithKline (4) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (3) · Eveliqure Biotechnologies GmbH (3)
What is being tested here
Drugs under test in Dysentery, Bacillary studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Shigella sonnei | 1 | 0 | 3 |
| Azithromycin | 1 | 0 | 2 |
| CVD-1208S | 0 | 0 | 3 |
| MenACWY | 0 | 0 | 1 |
| Haemophilus Influenzae B Vaccine | 0 | 0 | 1 |
| Rifaximin | 0 | 1 | 1 |
| Butyric Acid | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- May 2027Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years Old · Eveliqure Biotechnologies GmbH
- Aug 2027Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants · International Vaccine Institute
Who these studies take
Of the 5 Dysentery, Bacillary studies recruiting now, 0 (0%) set no upper age limit and 5 (100%) stop at 75 or younger. 1 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 4 (80%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 4 (80%) | 4 (80%) |
| 30 | 4 (80%) | 4 (80%) |
| 40 | 4 (80%) | 4 (80%) |
| 50 | 2 (40%) | 2 (40%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 61 studies, recruiting or not: 92% stop at 75 or younger and 92% at 65; 38% take children; 2% are for women only and 0% for men only; 84% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Dysentery, Bacillary studies take
Of 15 phase 1 interventional studies under Dysentery, Bacillary, half reached primary completion within 10 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 10 mo7–24 · 15 studies | — | — |
| Phase 2 | 11 mo9–30 · 11 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 13, 2026.
Results posted1
Studies
Recruiting first, then most recently updated. Showing 50 of 61. Browse all 61 → or search them.
- Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and InfantsNot yet recruitingNCT07666750Phase 1/2
- The Impact of Shigellosis and Recommended Treatment in ChildrenRecruitingNCT07433426Phase 22 countries
- First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young AdultsRecruitingNCT07205926Phase 11 country
- Safety, and Efficacy Study of ShigETEC, a Live, Attenuated, Oral Combination Vaccine to Prevent Shigella and ETEC Disease Delivered to Healthy Adults Ages 18 to 50 Years OldRecruitingNCT07049159Phase 21 country
- Shigella Sonnei 53G Human Infection Study in Kenyan AdultsRecruitingNCT05959616Phase 11 country
- InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and ZambiaRecruitingNCT05961059Phase 11 country
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsCompletedNCT06663436Phase 21 country
- A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate VaccineCompletedNCT06615375Phase 21 country
- Tebipenem Trial in Children With ShigellosisCompletedNCT05121974Phase 21 country
- Phase 2 Shigella Vaccine and ChallengeCompletedNCT04242264Phase 21 country
- Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.CompletedNCT06523231Phase 21 country
- A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan InfantsCompletedNCT04056117Phase 1/21 country
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsCompletedNCT05073003Phase 1/22 countries
- Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate VaccineActive, not recruitingNCT06838195Phase 31 country
- Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122CompletedNCT04634513Phase 11 country
- ShigETEC Vaccine Study in BangladeshCompletedNCT05987488Phase 11 country
- Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of ShigellosisActive, not recruitingNCT05182749Phase 1/21 country
- Controlled Human Infection Model Challenge/RechallengeCompletedNCT04992520Phase 11 country
- Enterics for Global Health (EFGH)Active, not recruitingNCT060478217 countries
- Egg Intervention During Pregnancy in IndonesiaActive, not recruitingNCT04694235Not applicable1 country
- Shigella CVD 30000: Study of Responses to Vaccination With Shigella VaccineCompletedNCT04078022Phase 21 country
- A Study to Investigate the Safety and Immunogenicity of the SF2a-TT15 Synthetic Carbohydrate-based Conjugate Vaccine Against Shigella Flexneri 2aCompletedNCT04602975Phase 21 country
- Ciprofloxacin Versus Azithromycin for Children Hospitalised With DysenteryCompletedNCT03854929Phase 41 country
- A Baseline Study in Support of Clinical Evaluation of an Oral Shigella Vaccine Development in AfricaCompletedNCT043129062 countries
- Phase 1 Trial for Safety, Tolerability, and Immunogenicity of a Live, Attenuated, Oral Shigella/ETEC Combination Vaccine to Healthy AdultsCompletedNCT05409196Phase 11 country
- Immunogenicity and Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 3 Months to 5 Years OldCompletedNCT04865497Phase 21 country
- Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 YearsStatus unknownNCT05156528Phase 31 country
- Safety Study of Inactivated Shigella Whole Cell Vaccine in AdultsCompletedNCT01509846Phase 11 country
- Dose Escalating Study of Intramuscular Invaplex[AR-DETOX]CompletedNCT03869333Phase 11 country
- Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMPCompletedNCT01531530Phase 11 country
- Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIbTerminatedNCT00866242Phase 21 country
- Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIaTerminatedNCT00866476Phase 21 country
- Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)CompletedNCT02445963Phase 11 country
- Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2aCompletedNCT02646371Phase 21 country
- Phase 1 Study of dmLT ID Vaccination in Healthy AdultsCompletedNCT02531685Phase 11 country
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy AdultsCompletedNCT03527173Phase 21 country
- Shigella WRSS1 Vaccine Trial in BangladeshCompletedNCT02934178Phase 11 country
- Rifaximin for Prevention of Travellers' DiarrheaCompletedNCT00742469Phase 31 country
- Shigella Sonnel O-SPC/rBRU Conjugate VaccineCompletedNCT01369927Phase 11 country
- A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP StudyCompletedNCT03089879Phase 11 country
- Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge StrainCompletedNCT02816346Phase 11 country
- Safety Study of Live Attenuated Oral Shigella (WRSS1) Vaccine in Bangladeshi Adults and ChildrenCompletedNCT01813071Not applicable1 country
- Multidrug Resistant Shigella Infection in BangladeshStatus unknownNCT037781251 country
- Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3CompletedNCT01336699Phase 11 country
- A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.CompletedNCT02017899Phase 11 country
- Safety and Efficacy Study of WRSS1, a Shigella Sonnei Vaccine CandidateCompletedNCT01080716Phase 1/21 country
- Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 MonthsCompletedNCT03561181Phase 11 country
- Healthy Adult Volunteer Study for Two Doses of a Shigella VaccineCompletedNCT00210288Phase 22 countries
- SF2a-TT15 Conjugate Vaccine in Healthy Adult VolunteersCompletedNCT02797236Phase 11 country
- Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in AdultsWithdrawnNCT03038243Phase 21 country